Devyser Diagnostics aims to grow by turning more transplant testing in the U.S. into everyday clinical use as reimbursement and approvals fall into place. At the same time, growing demand for prenatal and blood-typing tests across major labs could lift repeat kit sales, but the story depends on key regulatory decisions and a few large partners delivering as expected.Read more
Devyser Diagnostics is pushing into growing genetic testing markets, but the path to bigger profits may be bumpier than it looks as it keeps spending on research and its U.S. rollout. Heavy reliance on big partners and uncertain reimbursement decisions could slow adoption and keep margins under pressure before longer-term demand shows up.Read more
No trending discussion available.
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the interpretation of test results. The company was incorporated in 2004 and is headquartered in Årsta, Sweden.
